Vincerx Pharma Inc. has received FDA clearance of its IND application for VIP-236, a small molecule-drug conjugate (SMDC) for the treatment of advanced solid tumors. A first-in-human study for advanced or metastatic solid tumors is expected to start in the first quarter of next year.